Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-01-26 4:23 pm Sale | 13D | BridgeBio Pharma Inc. BBIO | Eidos Therapeutics Inc. EIDX | 0 0.000% | -44,651,896 (Position Closed) | View |
| 2021-01-26 09:00 am Sale | 13D | Eidos Therapeutics Inc. EIDX | BridgeBio Pharma Inc. BBIO | 1,000 100.000% | -24,574,501 (-100.00%) | View |
| 2020-10-15 4:17 pm Purchase | 13D | BridgeBio Pharma Inc. BBIO | Eidos Therapeutics Inc. EIDX | 44,651,896 36.400% | 44,651,896 (New Position) | View |
| 2020-10-07 5:00 pm Sale | 13D | Eidos Therapeutics Inc. EIDX | RA CAPITAL MANAGEMENT L.P. | 1,798,339 4.700% | -364,332 (-16.85%) | View |
| 2020-10-05 5:30 pm Unchanged | 13D | Eidos Therapeutics Inc. EIDX | BridgeBio Pharma Inc. BBIO | 24,575,501 63.700% | 0 (Unchanged) | View |
| 2020-02-11 12:57 pm Sale | 13G | Eidos Therapeutics Inc. EIDX | VIKING GLOBAL INVESTORS LP | 0 0.000% | -1,986,201 (Position Closed) | View |